SCHEMBL378687

SCHEMBL378687

Cc1nc(-c2ccc(C(=O)N3CCC(C(=O)N[C@@H](C)C4CCCCC4)(c4ccccc4)CC3)cc2)no1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.44
TSHR P16473 1/20 0.41
POLB P06746 1/20 0.41
SMYD3 Q9H7B4 1/20 0.40
P2RX3 P56373 2/20 0.39
HSD11B1 P28845 2/20 0.39
OPRL1 P41146 1/20 0.39
HDAC4 P56524 4/20 0.39
LMNA P02545 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPK14 Q16539 1/20 0.38
RHOA P61586 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378032 0.88 TSHR (0.41) MGLLTSHRPOLBP2RX3OPRL1
SCHEMBL379056 0.85 MGLL (0.47) MGLLTSHRHDAC4ALDH1A1CA12
SCHEMBL13092247 0.82 MGLL (0.44) MGLLTSHRHDAC4LMNAALDH1A1
SCHEMBL3099478 0.81 MGLL (0.55) MGLLTSHRHDAC4LMNAALDH1A1
SCHEMBL378776 0.80 TACR3 (0.40) P2RX3
SCHEMBL7908120 0.79 MGLL (0.42) MGLLTSHRSMYD3HDAC4LMNA
SCHEMBL13102753 0.79 EPHX2 (0.46) POLBHSD11B1OPRL1LMNAALDH1A1
SCHEMBL378760 0.79 EPHX2 (0.46) POLBHSD11B1OPRL1LMNAALDH1A1
SCHEMBL13092395 0.77 TACR3 (0.42) MGLLHDAC4LMNAALDH1A1
SCHEMBL13092250 0.77 TSHR (0.41) TSHRPOLBSMYD3OPRL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP claimed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 MGLL 3999/4885TSHR 895/4885POLB 2329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.